Forge Biologics Receives Priority Medicines (PRIME) Designation from the European Medicines Agency (EMA) for Novel Gene Therapy FBX-101 for the Treatment of Patients with Krabbe Disease
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced that the European Medicines Agency (EMA) has granted priority medicines (PRIME) designation to FBX-101, Forge’s lead adeno-associated virus (AAV) drug candidate and novel gene therapy for treating patients with Krabbe disease.
PRIME is a regulatory designation by the EMA that provides early and proactive support to developers of promising medicines, to advance and speed up their development and usher them to reach patients faster. The goal is to help patients benefit as early as possible from innovative new therapies that have demonstrated the potential to significantly address and treat patients that have an unmet medical need.
“We are grateful to the EMA for recognizing FBX-101 as a potentially transformative medicine for patients living with this life-threatening and devastating disease,” said Christopher Shilling, Senior Vice President of Regulatory Affairs and Quality at Forge. “Through the enhanced interactions with the EMA granted by the PRIME designation, we will advance and expedite the development of FBX-101 as the leading worldwide gene therapy for patients with Krabbe disease.”
The designation follows positive safety and efficacy data from the ongoing Phase 1/2 RESKUE trial. This positive clinical data was presented by Maria Escolar, M.D., Forge’s Chief Medical Officer at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium in August 2022, and updated in October at the 29th Congress of European Society of Gene & Cell Therapy (ESGCT). The results demonstrated that systemically delivered FBX-101 administered after hematopoetic stem cell transplant (HSCT) is safe and well-tolerated in Krabbe patients. Patients in the low dose cohort demonstrated restoration of GALC enzyme activity, reduced psychosine, showed encouraging signs of normal myelination of brain white matter, and improved motor development as compared to untreated Krabbe patients or patients treated with HSCT alone.
Clinical data support preclinical observations that this gene therapy approach after HSCT infusion may lessen many of the immune challenges previously observed with systemic AAV gene delivery and may create a safer environment for gene replacement. Findings also support this novel approach for extending the delivery of gene replacement strategies to target metabolic diseases amenable to HSCT.
About Krabbe Disease
Krabbe disease is a rare neurodegenerative disease affecting about 1-2.5 in 100,000 people in the U.S. Krabbe disease is caused by autosomal recessive mutations in the galactocerebrosidase (GALC) gene, an enzyme responsible for the breakdown of certain types of sphingolipids, such as psychosine, associated with myelination of the nervous system. Without functional GALC, psychosine accumulates to toxic levels in cells, specifically in cells insulating the nerves in the brain and peripheral nervous system, causing rapid demyelination. Krabbe disease initially manifests as irritability, developmental delay, and progressive muscle weakness; symptoms rapidly advance to difficulty swallowing, breathing, worsening developmental delay, and vision and hearing loss. Infantile Krabbe disease (0 –12 months of age at onset) usually leads to death in untreated patients by 2 years of age. Late Infantile patients (12-36 months of age at onset) usually die by the age of six. The current standard of care, hematopoietic stem cell transplantation (HSCT), has been shown to stabilize cognitive decline and significantly improve long-term neurological outcomes when performed prior to symptom onset. However, HSCT does not correct the peripheral neuropathy that is progressive as the patient grows, leading to loss of gross motor skills and eventually death. Early diagnosis is key for treating Krabbe patients before significant neurological damage has occurred. Currently, 10 states in the USA are conducting newborn screening for Krabbe disease. Infants who screen positive, meaning insufficient GALC activity is detected, undergo psychosine and mutation analysis to confirm the diagnosis and predict disease onset.
FBX-101 was developed to treat children with Krabbe disease. FBX-101 is an adeno-associated viral serotype rh10 (AAVrh10) gene therapy that is delivered intravenously after HSCT infusion. The vector delivers a functional copy of the GALC gene to cells in both the central and peripheral nervous system. FBX-101 has been shown to functionally correct the central and peripheral neuropathy associated with Krabbe, improve gross motor outcomes, and significantly prolong lifespan in animal models. This approach has the potential to overcome some of the immunological safety challenges observed in traditional AAV gene therapies and extend the duration of gene transfer.
About the RESKUE Trial
RESKUE a Phase 1/2 clinical trial to investigate the safety and efficacy of FBX-101 in patients with Infantile Krabbe disease. It is a nonblinded, non-randomized dose escalation study of intravenous AAVrh10 after HSCT infusion, in which subjects receive standard of care hematopoietic cell transplantation for Krabbe Disease, followed by a single infusion of an adeno-associated virus gene therapy product. Extensive natural history subjects will be used to compare as control group. More information on the RESKUE trial can be found online at https://www.clinicaltrials.gov/ct2/show/NCT04693598.
About Forge Biologics
Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea to reality. Forge’s 200,000 square foot facility utilizes 20 cGMP suites in Columbus, Ohio, the Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV manufacturing and hosts scalable, end-to-end manufacturing services. Offerings include process and analytical development, plasmid DNA manufacturing, viral vector manufacturing, final fill, as well as regulatory consulting support to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit www.forgebiologics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Associate Director, Marketing and Communications
Families and Clinician Inquiries
Maria Escolar, M.D.
Chief Medical Officer
Senior Vice President, Head of Business Development
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Belkin Introduces Samsung Approved Screen Protectors for New Samsung Galaxy S23, S23+ and S23 Ultra Smartphones2.2.2023 03:00:00 EET | Press release
Belkin, a global consumer electronics leader in device protection, today introduces its ScreenForce™ TrueClear Curve screen protectors for the new Samsung Galaxy S23 series. These products have not only passed Belkin’s rigorous design and engineering quality tests but have also received the “Designed for Samsung” badge through the Samsung Mobile Accessory Partnership Program (SMAPP). “Belkin has led the accessories market in innovation and technology leadership for 40 years. People trust us to build the world’s best products to connect, power and protect their devices, and to put our customers and partners first,” said Steve Malony, CEO, Belkin. “Having Samsung’s additional stamp of approval allows our customers to have comfort and confidence that a Belkin product was designed perfectly for their brand-new device.” Belkin ScreenForce™ TrueClear Curve Blue Light Filter Screen Protectors are available for all three new Samsung devices and are engineered to accentuate the design of the de
Airswift Technology and Cloud Payments Partner to Enable Instant Access to Crypto with VISA and MasterCard2.2.2023 01:04:00 EET | Press release
Airswift Technology Limited, a leading Web3.0 native payment company, and Cloud Payments, a digital payments and banking technology platform provider have joined forces to enable cryptocurrency spenders with instant access to crypto at the points-of-sale using VISA and MasterCard payment methods. The collaboration will simplify crypto-based purchases by providing crypto on-ramping and NFT purchasing using VISA and MasterCard with optimized exchange rates. This offers crypto spenders increased convenience when shopping for retail goods and digital assets. “Millions of Web2.0 consumers are ready to onboard to Web3.0, but are not familiar with existing Decentralized Finance (DeFi) on-ramps,” said Dr. Yan Zhang, co-founder and CEO of Airswift. “So we’ve worked together to integrate Cloud Payments' simple, credit-card based crypto purchasing tools into our easy-to-use crypto payment platform. This feature lets you seamlessly on-ramp to and spend crypto right at the checkout without ever lea
Swave Photonics, QART Medical, and PhosPrint win big at 2023 SPIE Startup Challenge2.2.2023 00:02:00 EET | Press release
Yesterday, at a ceremony during SPIE Photonics West, Swave Photonics – with their Holographic eXtended Reality chips based on proprietary diffractive photonics technology – was announced the winner of the $10,000 top prize at the 13th annual SPIE Startup Challenge. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230201005834/en/ Jenoptik’s Ralf Kuschnereit, far left, Swave Co-Founder and Chief Product Officer Theo Marescaux, Swave CEO Mike Noonen, and 2023 SPIE Vice President Peter de Groot. Credit: Joey Cobbs. QART Medical, utilizing biophotonics and data for 3D analysis of sperm cells during IVF, received $5,000 for second place. PhosPrint came in third, winning $2,500, with their novel bioprinting technology that repairs in vivo human tissue during surgery. All cash prizes are provided by SPIE Startup Challenge Founding Partner Jenoptik. The SPIE Startup Challenge, a pitch competition held annually by SPIE, the internation
Q4 Inc. to Report Fourth Quarter 2022 Results on March 1st2.2.2023 00:00:00 EET | Press release
Q4 Inc. (TSX: QFOR), ("Q4" or the "Company") a leading capital markets communications platform, plans to release its fourth quarter and full year 2022 financial results before the market opens on Wednesday, March 1, 2023. In conjunction with this release, the company will hold a video webcast led by CEO Darrell Heaps, on the Q4 Virtual Events Platform at 9:30 a.m. ET on March 1, 2023. Q4 2022 Earnings Release and Conference Call Details Participants can register in advance or access the webcast live at https://events.q4inc.com/attendee/712032670. Supplemental materials will be available at least fifteen minutes prior to the start of the event. A replay of the webcast will be available at investors.q4inc.com shortly after the event concludes. Audience questions will be taken real-time via the Q4 Platform. Investors can also submit their questions in advance to email@example.com or via our IR website. We will do our best to respond to your questions either on the webcast, if time permits or s
Tanium Appoints Dan Streetman as Chief Executive Officer1.2.2023 22:00:00 EET | Press release
Tanium, a leading IT operations and security management company and the premier supplier of converged endpoint management (XEM), today announced the appointment of Dan Streetman to the role of chief executive officer. Orion Hindawi, who is the co-founder and current CEO of Tanium, will assume the role of executive chairman. In this new role, Orion will continue to drive the strategic vision and technical innovation at Tanium as well as continue his engagement with Tanium’s strategic partners and customers. David Hindawi, co-founder of Tanium, will transition to chairman emeritus. In his new role, Streetman will continue to strengthen Tanium’s commitment to protecting enterprises, organizations, and their people, while fortifying and evolving the company’s customer-facing operations, partner strategy, product strategy, and development. Streetman will build on the strong market momentum that Tanium has seen, including coming off a record fiscal year in terms of revenue and new customer g
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom